KRAS and neoplasm: Specifically cluster 1 (29.2% of patients), defined as “immunological subtype”, exhibited significant correlations with MSI status, high tumor mutational burden (TMB), and celiac disease; cluster 2 (16.7% of patients), called “DNA Damage Repair (DDR)‐like”, presented with mutations in BRCA2 in all cases and other genes involved in homologous DNA pairing and strand exchange, with potential benefit from poly (ADP‐ribose) polymerase (PARP) inhibitors (PARPi), and cluster 3 (54.1% of patients), called “Colon‐like”, characterized by genetic alterations in TP53, KRAS, PIK3CA, and APC [20].